Pulmonology Advisor

New Risk Model May Help Define Actionable Treatment Goals for IPF and ILD

A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.
ascopubs.org

Diffusing capacity for carbon monoxide (DLCO) change and outcome in advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICIs).

Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
Managed Healthcare Executive

FDA assigns goal date for Molbreevi for rare lung disease

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.
Healio

Diffusing capacity ‘strongly predicted’ mortality in COPD patients

Please provide your email address to receive an email when new articles are posted on . All-cause mortality in COPD patients was “strongly predicted” by diffusing capacity of the lung for carbon ...
National Academies of Sciences%2c Engineering%2c and Medicine

Requirements for Pulmonary Function Testing in Social Security Disability Evaluations

The Social Security Administration has requested the National Academies of Sciences, Engineering, and Medicine to review the latest published research and science and produce a report addressing best ...